Tenecteplase versus alteplase (TENVALT): A study comparing two thrombolytic agents in acute ischemic stroke

被引:0
|
作者
Sundar, Kaushik [1 ]
Bhirud, Lomesh [1 ]
Panwar, Ajay [1 ]
Cherian, Jerin Jose [2 ]
Paul, Eldho Mathew [3 ]
Kuruttukulam, Gigy Varkey [1 ]
机构
[1] Rajagiri Hosp, Dept Intervent Neurol, Kochi, Kerala, India
[2] Indian Council Med Res, Delhi, India
[3] Rajagiri Hosp, Dept Pharmacol, Kochi, Kerala, India
关键词
Alteplase; tenecteplase; stroke; thrombolysis; efficacy; safety; OPEN-LABEL;
D O I
暂无
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background & Objective: The Indian data comparing the efficacy and safety outcomes of tenecteplase and alteplase in acute ischemic stroke is scarce. We aimed to compare the outcomes of two agents in an Indian population. Methods: TENVALT study was a single centre, retrospective study. Patients aged 18 years or older with acute ischemic stroke were included in this study if they presented within 3 hours of symptom onset and had a deficit with National Institute of Health Stroke Scale (NIHSS) score > 4, had a modified Rankin score (mRS) of 2 or less before the stroke onset and had no evidence of hemorrhage on non-contrast computed tomography of brain. A good functional recovery (mRS score of 0-2) at the end of three months was defined as the primary efficacy outcome. The development of symptomatic intracerebral hemorrhage was considered as the primary safety outcome. Results: A total of 120 patients (alteplase, n=65; tenecteplase, n=55) underwent stroke thrombolysis during this study. The mean age of the presentation in tenecteplase group was 66.6 years and in alteplase group was 62.5 years. Most of the study subjects were males in both the groups (tenecteplase, 78.2%; alteplase, 61.5%). Hypertension was the most common comorbidity in both the groups (tenecteplase, 67.3%; alteplase, 76.9%). Median mRS score at 3 months of follow up was 2 in tenecteplase and 1 in alteplase group; however, the difference between the total number of patients having good functional recovery (mRS 0-2) in the two groups was not statistically significant (tenecteplase 74.5 vs alteplase 87.7%, P=0.09). The total number of patients who had symptomatic intracranial hemorrhage was comparable between the two groups (tenecteplase, 5.5%; alteplase, 6.2%). Conclusion: Tenecteplase appears to be an efficacious alternative to alteplase for stroke thrombolysis and may be better suited to developing countries considering its low cost and ease of administration.
引用
收藏
页码:203 / 208
页数:6
相关论文
共 50 条
  • [21] Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis
    A. Thelengana
    Divya M. Radhakrishnan
    Manya Prasad
    Amit Kumar
    Kameshwar Prasad
    Acta Neurologica Belgica, 2019, 119 : 359 - 367
  • [22] REAL-WORLD USE TRENDS OF ALTEPLASE VERSUS TENECTEPLASE FOR ACUTE ISCHEMIC STROKE
    Attridge, Rebecca
    Gilster, Alec
    Johnson, Samuel
    CRITICAL CARE MEDICINE, 2024, 52
  • [23] Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis
    Thelengana, A.
    Radhakrishnan, Divya M.
    Prasad, Manya
    Kumar, Amit
    Prasad, Kameshwar
    ACTA NEUROLOGICA BELGICA, 2019, 119 (03) : 359 - 367
  • [24] Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Systematic Review and Meta-analysis
    Singh, Alok
    Singh, Madhusudan Prasad
    Gaikwad, Nitin
    Kannauje, Pankaj Kumar
    ANNALS OF NEUROSCIENCES, 2024, 31 (02) : 132 - 142
  • [25] Coagulation and Fibrinolytic Activity of Tenecteplase and Alteplase in Acute Ischemic Stroke
    Huang, Xuya
    Moreton, Fiona Catherine
    Kalladka, Dheeraj
    Cheripelli, Bharath Kumar
    MacIsaac, Rachael
    Tait, R. Campbell
    Muir, Keith W.
    STROKE, 2015, 46 (12) : 3543 - 3546
  • [26] Thrombolysis in ischemic stroke: tenecteplase or alteplase
    Benjebara, H.
    Najmi, I.
    Chtaou, N.
    El Midaoui, A.
    Souirti, Z.
    Belahsen, M. F.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [27] Is Tenecteplase a Viable Alternative to Alteplase in the Treatment of Acute Ischemic Stroke?
    Vaishnav, Anand Girish
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2022, 25 (05) : 794 - 795
  • [28] Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase
    Yang, Nan
    Lee, Hangil
    Wu, Chuanjie
    BRAIN CIRCULATION, 2023, 9 (02) : 61 - 63
  • [29] Comparative safety of tenecteplase vs alteplase for acute ischemic stroke
    Flint, Alexander C.
    Eaton, Abigail
    Melles, Ronald B.
    Hartman, Jonathan
    Cullen, Sean P.
    Chan, Sheila L.
    Rao, Vivek A.
    Nguyen-Huynh, Mai N.
    Kapadia, Brij
    Patel, Nihar U.
    Klingman, Jeffrey G.
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2024, 33 (01):
  • [30] Comparative Analysis of Tenecteplase versus Alteplase in Acute Ischemic Stroke: A Multicentric Observational Study from Eastern India
    Dutta, Arpan
    Gupta, Subhadeep
    Chakraborty, Uddalak
    Mondal, Chayan
    Banerjee, Soumozit
    Das, Deep
    Jatua, Sanat K.
    Chakrabarty, Susanta
    Misra, Samiran
    Bhattacharya, Jishnu
    Datta, Samir K.
    Ghosh, Somnath
    Sanyal, Debasish
    Sarkar, Arnab
    Ray, Biman K.
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2024, 27 (03) : 269 - 273